|Mr. Pietro Bersani CPA, J.D.||CEO & Director||167.76k||N/A||1968|
|Dr. Scott Dahlbeck M.D., Pharm.D., PharmD||Chief of Staff||442.12k||N/A||1962|
|Mr. Daniel Clark||Chief Financial Officer||N/A||N/A||1989|
|Dr. David M. Spencer||Chief Scientific Officer||N/A||N/A||1962|
|Dr. Michael Ryan Ph.D.||Chief Bioinformatics Officer||N/A||N/A||1967|
Kiromic BioPharma, Inc., an artificial intelligence driven, end-to-end allogenic cell therapy company, develops multi-indication allogeneic T cell therapies for solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy. It has license agreements with Mercer University; CGA 369 Intellectual Holdings, Inc.; and Longwood University, as well as research and development collaboration agreements with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
Kiromic BioPharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.